PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

BACKGROUND: Preclinical studies suggest that Reed–Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chromosome 9p24.1 increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and promote their induction thr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Ansell, Stephen M., Lesokhin, Alexander M., Borrello, Ivan, Halwani, Ahmad, Scott, Emma C., Gutierrez, Martin, Schuster, Stephen J., Millenson, Michael M., Cattry, Deepika, Freeman, Gordon J., Rodig, Scott J., Chapuy, Bjoern, Ligon, Azra H., Zhu, Lili, Grosso, Joseph F., Kim, Su Young, Timmerman, John M., Shipp, Margaret A., Armand, Philippe
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4348009/
https://ncbi.nlm.nih.gov/pubmed/25482239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1411087
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars